News
FDA Gives Marketing Nod to Blood Test for Diagnosing Alzheimer Disease
The Lumipulse test reduces the need for positron emission tomography (PET) and the need to collect cerebrospinal fluid (CSF) via invasive lumbar puncture, which is required by previously approved tests. The Lumipulse test simply requires a blood sample.
A new study published in the Neurology and Urodynamics journal reveals that long-term use of anticholinergic drugs, commonly ...
While Alzheimer's disease is mostly considered a disorder of the brain, emerging evidence suggests that the condition also affects other organs of the body. Working with the laboratory fruit fly, ...
Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...
MedPage Today on MSN2d
Alzheimer's Drug Used Mainly by Relatively Affluent, Urban White MenLecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback